VYNE Therapeutics to Present at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference

July, 19 2022

BRIDGEWATER, N.J., July 19, 2022 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that Iain Stuart, Ph.D., Chief Scientific Officer of VYNE, will be presenting at the B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) on July 27, 2022. B&T Cell-Mediated Autoimmune Disease Drug Development Conference (in-person) – Presentation Details Presentation Date: July 27, 2022 Presenter: Iain Stuart, Ph.D., Chief Scientific Officer of VYNE Presentation Track: Harnessing Autoantibody Signatures and Mapping Out the B&T Cell-Mediated Autoimmune Disease Landscape Presentation…

Read More